<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105672</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308XZH</org_study_id>
    <nct_id>NCT05105672</nct_id>
  </id_info>
  <brief_title>A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical Cancer</brief_title>
  <official_title>A Single-Arm, Single-Center Phase II Clinical Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in The Treatment of Stage IIA2 To IVA (2018 FIGO) Locally Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Xuzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Xuzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, single-center phase II clinical study to explore the efficacy and&#xD;
      safety of sintilimab combined with concurrent chemoradiation therapy as treatment in women&#xD;
      with locally advanced cervical cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Time from diagnosis of disease to disease progression or death due to any cause</time_frame>
    <description>2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from diagnosis of disease of treatment until death due to any cause</time_frame>
    <description>2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADRs and tolerance</measure>
    <time_frame>1 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Sintilimab</condition>
  <arm_group>
    <arm_group_label>chemoradiotherapy + Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given intravenous administration of sintilimab (200mg, q3w), cisplatin(75 mg/m², q3w) and Radiotherapy. After completing 2 cycles of concurrent chemoradiation, the Participants will continue to use 4 cycles of sintilimab (200mg, q3w) and cisplatin(75 mg/m², q3w) as maintenance therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiotherapy + Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>chemoradiotherapy + Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiotherapy (EBRT)</intervention_name>
    <description>Undergo pelvic EBRT</description>
    <arm_group_label>chemoradiotherapy + Sintilimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>brachytherapy</description>
    <arm_group_label>chemoradiotherapy + Sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has high-risk locally advanced cervical cancer (LACC): The International Federation of&#xD;
             Gynecology and Obstetrics (FIGO) 2018 Stage IB3 or FIGO 2018 Stages IIA2-IVA.&#xD;
&#xD;
          -  Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Has radiographically evaluable disease, either measurable or non-measurable per RECIST&#xD;
             1.1&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic functions:Hemoglobin &gt; 9.0 g/dl; Neutrophils&#xD;
             &gt; 2000 cells/μl; ANC &gt; 1.5 × 10^9/L;Platelets &gt; 100 × 10^9/L;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death receptor 1 (PD-1),&#xD;
             anti-programmed cell death receptor ligand 1 (PD-L1), or anti-programmed cell death&#xD;
             receptor ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or&#xD;
             co-inhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein 4&#xD;
             (CTLA-4), OX-40, CD137).&#xD;
&#xD;
          -  Has a known history of Human Immunodeficiency Virus (HIV) infection.&#xD;
&#xD;
          -  Prior malignancies (other than curable non-melanoma skin cancer) within 5 years&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoxiao Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Affiliated Hospital of Xuzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaoxiao Liu, MD</last_name>
    <phone>18752113909</phone>
    <email>281656652@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoxiao Liu, MD</last_name>
      <phone>18752113909</phone>
      <email>281656652@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoxiao Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

